Last reviewed · How we verify
NCT05204160
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Phase 2 trial testing Pembrolizumab in Plasma Cell Myeloma. Withdrawn.
27 February 2024
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 11 April 2022 |
| Primary completion | 27 February 2024 |
| Estimated completion | 27 February 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pembrolizumab (pembrolizumab) — full drug profile →
Conditions studied
- Plasma Cell Myeloma — all drugs for Plasma Cell Myeloma →
Sponsor
Emory University
Who can join
18 and older, any sex, with Plasma Cell Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR-T cell therapy in Multiple Myeloma: current status and future challenges.
Swan D, Madduri D, Hocking J. · · 2024 · cited 32× · PMID 39592597 · DOI 10.1038/s41408-024-01191-8 -
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
Abramson HN. · · 2023 · cited 16× · PMID 37958658 · DOI 10.3390/ijms242115674 -
Checkpoint inhibition in hematologic malignancies.
Tsumura A, Levis D, Tuscano JM. · · 2023 · cited 14× · PMID 37920162 · DOI 10.3389/fonc.2023.1288172 -
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies.
Shang J, Hu S, Wang X. · · 2024 · cited 13× · PMID 38396050 · DOI 10.1186/s40164-024-00481-y -
Updates on CAR T cell therapy in multiple myeloma.
Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, et al · · 2024 · cited 10× · PMID 39261906 · DOI 10.1186/s40364-024-00634-5 -
Rediscovering hemostasis abnormalities in multiple myeloma: The new era.
Huang Y, Wang C, Wang H, Liu H, et al · · 2024 · PMID 39055831 · DOI 10.1016/j.heliyon.2024.e34111
Verify or expand the search:
- PubMed search for NCT05204160
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pembrolizumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
Other recruiting trials for Plasma Cell Myeloma
Currently open trials in the same condition.
- NCT04876248 — Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Po · Phase 2 · active not recruiting
- NCT05561387 — Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Me · Phase 3 · recruiting
- NCT05892393 — Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma · Phase 1 · recruiting
- NCT05669989 — International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefi · Phase 2 · active not recruiting
- NCT05392946 — Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study · Phase 1, PHASE2 · active not recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05204160 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 3 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05204160.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing